Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897088 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
A Phase 3 study of Scalp Psoriasis, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT03897088: Completed Phase 3 study of Scalp Psoriasis, sponsored by Sun Pharmaceutical Industries Limited.
NCT03897088 is a Phase 3 study of Scalp Psoriasis that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 231 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03897088, a Phase 3 study of Scalp Psoriasis, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
Conditions Studied
Interventions
- DRUG PART 1: Double-blind Placebo-controlled
- DRUG PART 2: Double-blind Active Treatment Extension
Study Locations (20)
California
- SPARC Site 18 - Encinitas
- SPARC Site 7 - Fountain Valley
- SPARC Site 3 - Fremont
- SPARC Site 12 - Huntington Beach
- SPARC Site 9 - Los Angeles
- SPARC Site 2 - Los Angeles
- SPARC Site 14 - Santa Monica
Florida
- SPARC Site 21 - Coral Gables
- SPARC Site 19 - Margate
- SPARC Site 5 - Sweetwater
Texas
- SPARC Site 17 - Cypress
- SPARC Site 11 - Houston
- SPARC Site 6 - Webster
New York
- SPARC Site 4 - Forest Hills
- SPARC Site 16 - New York
New Jersey
- SPARC Site 13 - East Windsor
Ohio
- SPARC Site 01 - Beachwood
Oregon
- SPARC Site 20 - Portland
Rhode Island
- SPARC Site 8 - Johnston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2019-03-29 |
| Est. Completion | 2022-02-17 |
| Phase | Phase 3 |
What the finished NCT03897088 record still lists
NCT03897088 is an interventional study that assigns participants to a tested intervention. The registered 231 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Scalp Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which PART 1: Double-blind Placebo-controlled is the first listed.
NCT03897088 names 20 study sites across 9 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT03897088 about?
NCT03897088 is a clinical study titled "Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis". This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
What is the current status of trial NCT03897088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 231 participants. The study started on 2019-03-29. Estimated completion is 2022-02-17.
What conditions does trial NCT03897088 study?
This clinical trial studies the following conditions: Scalp Psoriasis.
What interventions are being tested in trial NCT03897088?
The interventions under investigation include: PART 1: Double-blind Placebo-controlled (DRUG), PART 2: Double-blind Active Treatment Extension (DRUG).
Who is sponsoring clinical trial NCT03897088?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03897088 being conducted?
This trial has 20 study locations across California, Florida, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scalp Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03897088's enrollment target sits among peer trials
231 1300th of 2000 higher than 697 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077099 · 231 participants · Phase 1
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
- NCT05019495 · 231 participants · NA
Optimizing Tobacco Treatment Delivery for People Living With HIV
- NCT06023589 · 231 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- NCT06734351 · 231 participants · Phase 3
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI